Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

Roche Holdings AG (OTC:RHHBY) connected Tuesday released statistically important last wide endurance (OS) results from the signifier III APHINITY survey successful radical with quality epidermal maturation origin receptor 2 (HER2)-positive early-stage bosom cancer.
After 10 years, the hazard of decease was…

This communicative appeared connected benzinga.com, 2025-05-13 21:37:09.